Article
Fc-engineered EGF-R antibodies mediate improved antibody-dependent cellular cytotoxicity (ADCC) against KRAS-mutated tumor cells.
Cancer science - 1 May 2010
Schlaeth Martin, Berger Sven, Derer Stefanie, Klausz Katja, Lohse Stefan, Dechant Michael, Lazar Greg A, Schneider-Merck Tanja, Peipp Matthias, Valerius Thomas
Abstract excerpt
Oncogenic mutations of the KRAS gene have emerged as a common mechanism of resistance against epidermal growth factor receptor (EGF-R)-directed tumor therapy. Mutated KRAS leads to ligand-independent activation of signaling pathways downstream of EGF-R. Thereby, direct effector mechanisms of EGF-R antibodies, such as blockade of ligand binding and inhibition of signaling, are bypassed. Thus, a humanized variant...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.